Content Team Content Team

The Biotech Reset: Capital Returns with Conditions

Biotech funding is returning, but on different terms. Larger late-stage rounds, a cautiously reopening IPO window, and more disciplined investors are reshaping how biotech companies raise capital and what it takes to support a defensible valuation.

Read More
Content Team Content Team

The Impact of AI on SaaS

Artificial intelligence is reshaping the SaaS model. Venture capital is concentrating around AI-enabled platforms with proprietary data, outcome-based pricing, and defensible advantages that influence how software companies grow and are valued.

Read More
Content Team Content Team

Key Updates Founders Should Know About QSBS in 2025

New QSBS rules under the One Big Beautiful Bill Act expand eligibility, raise exclusion caps, and shorten holding periods. Learn what founders need to know in 2025 and how Redwood can help document eligibility through defensible valuation.

Read More